Pazopanib

For research use only.

Catalog No.S3012 Synonyms: GW786034

53 publications

Pazopanib Chemical Structure

CAS No. 444731-52-6

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces cathepsin B activation and autophagy.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Pazopanib has been cited by 53 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces cathepsin B activation and autophagy.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWHxdZlmUW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;Mj64PYUuODVizszN MknSV2FPT0WU
human AN3-CA cell M2i4cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVnJcohq[mm2aX;uJI9nKGi3bXHuJGFPOy2FQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlA2KG6P NWPTe21xW0GQR1XS
human CGTH-W-1 cell NEXMWXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX\lcJd6UW6qaXLpeIlwdiCxZjDoeY1idiCFR2TIMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRyLkCxJI5O NXnLWZpHW0GQR1XS
human GDM-1 cell MoTnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX7DSmhoUW6qaXLpeIlwdiCxZjDoeY1idiCJRF2tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExOy57OTDuUS=> M1;C[HNCVkeHUh?=
human A204 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF;QTVRKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFkvODZibl2= Mmn3V2FPT0WU
human G-402 cell NHz0R2JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWXZ[nBuUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVU{OS56NDDuUS=> MlW5V2FPT0WU
human MFE-296 cell NH\YTY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2LCUGlvcGmkaYTpc44hd2ZiaIXtZY4hVU[HLUK5OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTlyMkKg{txO NGTYPXhUSU6JRWK=
human NOS-1 cell NFzrco9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWHJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;MD62OVk5PyEQvF2= M1XKfnNCVkeHUh?=
human KG-1 cell M4\afmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWjJcohq[mm2aX;uJI9nKGi3bXHuJGtINTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkexO|U2KM7:TR?= MnjpV2FPT0WU
human HT55 cell NIn4bW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEjEWGRKdmirYnn0bY9vKG:oIHj1cYFvKEiWNUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5PzhzIN88US=> Mk[xV2FPT0WU
human MG-63 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUnxXZBIUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODBzNE[g{txO NHW1WplUSU6JRWK=
human CCF-STTG1 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2O4NmlvcGmkaYTpc44hd2ZiaIXtZY4hS0OILWPUWGcyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XoxvJygTWM2OD1zLkC0PVgyKM7:TR?= NGjsVFJUSU6JRWK=
human RT-112 cell MkK4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWCxNGZFUW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjFyM{e2JO69VQ>? MmDlV2FPT0WU
human MC-IXC cell NYD0R5RlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXLHc5N3UW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjFzNUGyJO69VQ>? NH36XWZUSU6JRWK=
human HUTU-80 cell NX;ENYtqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2PzS2lvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjhzMEOg{txO M{jjbnNCVkeHUh?=
human MV-4-11 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVrJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM1PTBzIN88US=> MWHTRW5ITVJ?
human LCLC-103H cell NUX5SJhQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFTsPYVKdmirYnn0bY9vKG:oIHj1cYFvKEyFTFOtNVA{UCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7 M3vpXnNCVkeHUh?=
human G-401 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnLBTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFY1OjFizszN M{n0[HNCVkeHUh?=
human A704 cell NVr0cVBFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[wN|I{KM7:TR?= MXnTRW5ITVJ?
human ESS-1 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVXzOJRNUW6qaXLpeIlwdiCxZjDoeY1idiCHU2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjB|OU[g{txO Ml:1V2FPT0WU
human HLE cell MmOyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml35TY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[zPFA1KM7:TR?= NH65bmxUSU6JRWK=
human NY cell NVSxToFHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3zufGlvcGmkaYTpc44hd2ZiaIXtZY4hVlliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLki0PFIyKM7:TR?= NXjZZ5dHW0GQR1XS
human A427 cell MojJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYHJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkm4NFc2KM7:TR?= MoPqV2FPT0WU
human SK-N-DZ cell Mnq1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV7TRXA2UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMkO4NUDPxE1? M{DyO3NCVkeHUh?=
human J82 cell M1jEVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGo5OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwME[wPFgh|ryP MUnTRW5ITVJ?
human GI-1 cell NXz0eZNzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUXifpV7UW6qaXLpeIlwdiCxZjDoeY1idiCJST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zOjl3MTFOwG0> NE\1[mVUSU6JRWK=
human NCI-H716 cell Mn\4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVjFOVRbUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFcyPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwM{G2N|Mh|ryP MlPhV2FPT0WU
human SF126 cell NYXDSnZHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkTlTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOFc1PTlizszN M2fwSnNCVkeHUh?=
human H4 cell M17BTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFHtdINKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NVI3OiEQvF2= MYXTRW5ITVJ?
human LB831-BLC cell Mo\rS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIHoRpZKdmirYnn0bY9vKG:oIHj1cYFvKEyEOEOxMWJNSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUS1OlYh|ryP NUnIfIZiW0GQR1XS
human HCC1395 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHnzPVFKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{GzPVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV6MUW2JO69VQ>? NXHnOnRmW0GQR1XS
human LK-2 cell M4HyeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUXJcohq[mm2aX;uJI9nKGi3bXHuJGxMNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[0OVY6KM7:TR?= NIG2cXRUSU6JRWK=
human G-361 cell NFH2TpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoXiTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFQxQDJizszN NGK4RmhUSU6JRWK=
human NCI-H2342 cell NG[4TW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVu5XYRrUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT6gTWM2OD1|LkGzN|E3KM7:TR?= NWOyT4NTW0GQR1XS
human SK-LU-1 cell  NIDV[oxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWTTTZA2UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zOEe2O{DPxE1? MmPGV2FPT0WU
human IGROV-1 cell  NUexdHhmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYrJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI1PzF|IN88US=> NV\xT|VHW0GQR1XS
human EB2 cell NXTxc3NNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFrjXXZKdmirYnn0bY9vKG:oIHj1cYFvKEWEMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlgyPjhizszN MV3TRW5ITVJ?
human CAL-54 cell NHznTVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjWflBrUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ6M{[3JO69VQ>? M1LnPHNCVkeHUh?=
human LB1047-RCC cell MkDNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4HydWlvcGmkaYTpc44hd2ZiaIXtZY4hV0OXQj3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{OzF|Nkig{txO MXfTRW5ITVJ?
Daudi cell MoC4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV|MU[0JO69VQ>? NEDFbo9USU6JRWK=
human Daudi cell NHnmS5ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVPJcohq[mm2aX;uJI9nKGi3bXHuJGRifWSrIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62OlIyQSEQvF2= MoX3V2FPT0WU
human A172 cell MmHaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkezO|kh|ryP NXHVdYR[W0GQR1XS
human KGN cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4TidWlvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6wOlcxQSEQvF2= M2fhWnNCVkeHUh?=
human SNG-M cell NUfMfoFRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mmf1TY5pcWKrdHnvckBw\iCqdX3hckBUVkdvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFg3PjlizszN Mn7qV2FPT0WU
human SW1710 cell MoH0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3T0NmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PzNzODFOwG0> NVLvco0xW0GQR1XS
human HT29 cells NFvaV5ZRem:uaX\ldoF1cW:wIHHzd4F6 MlyzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVEK5JINmdGy|IHnuJJNmenWvIHPvcpRicW6rbnegcYVlcXWv MonrNVg3OjB|OEK=
human A375P cells MkLqVJJwdGmoZYLheIlwdiCjc4PhfS=> NVryXWxNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2WCClZXzsd{BqdiC|ZYL1cUBkd262YXnubY5oKG2nZHn1cS=> NGrJPJAyQDZ{MEO4Ni=>
human HN5 cells NGXmOmFRem:uaX\ldoF1cW:wIHHzd4F6 NIrDRpJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= M3TkfVE5PjJyM{iy
HUVEC NXHhOZN{TnWwY4Tpc44h[XO|YYm= Ml3HNUDPxE1? MYG2JIg> NYjp[2J7SW62aXHu[4lw\2WwaXOgZYN1cX[rdImgbY4hUFWYRVOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjD0eYJmKG[xcn3heIlwdiCjdDCwMlEhfU1iYX\0[ZIhPiCqcoOgZpkhVWG2cnnn[Ywh[XO|YYm= NY\FdmxrOjRyM{[wOFI>
human Daoy cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWfsSI9GUW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44Pzl2OTFOwG0> NVOyXnFQW0GQR1XS
human DMS-273 cell NYSyOpBST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYLJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk3OjB{IN88US=> M3\yT3NCVkeHUh?=
human KU812 cell NYCyTpBvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVjtT4JDUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzd6MUKg{txO MVnTRW5ITVJ?
human NCI-H727 cell NULFZotOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIHZcG5KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|I4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS52MEmwNUDPxE1? MYfTRW5ITVJ?
human P30-OHK cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3r6d2lvcGmkaYTpc44hd2ZiaIXtZY4hWDNyLV;IT{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDZ7NDFOwG0> MWXTRW5ITVJ?
human MIA-PaCa-2 cell Mn75S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmO4TY5pcWKrdHnvckBw\iCqdX3hckBOUUFvUHHDZU0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54MES2OkDPxE1? MVLTRW5ITVJ?
human TT cell NWXUN3ZYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXLqVGQ3UW6qaXLpeIlwdiCxZjDoeY1idiCWVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOlYzPCEQvF2= NIjZSmhUSU6JRWK=
human DK-MG cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1nORWlvcGmkaYTpc44hd2ZiaIXtZY4hTEtvTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlczODJ6IN8ccS=> NGHTc3RUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / PUMA ; 

PubMed: 27924057     


The expression of p53 or PUMA by western blotting analysis in HCT-116 cells treated with (left) 20 μM pazopanib for indicated hours or (right) with 1-20 μM pazopanib for 24 hours.

p-Akt / Akt ; 

PubMed: 27924057     


Akt is inhibited after pazopanib treatment in colon cells. The expression of P-Akt (S473) was detected by western blotting in (A) RKO or HT-29 cells after 20 μM pazopanib treatment for indicated times.

27924057
Growth inhibition assay
Cell viability; 

PubMed: 27924057     


Cell viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after 1, 5, 10, or 20 μM pazopanib treatment in HCT-116 cells. Data represent the mean ± SEM of four independent experiments.

27924057
In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034
Smiles CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04659343 Recruiting Drug: Medical treatment for metastatic renal cell carcinoma Kidney Cancer|Renal Cell Carcinoma Metastatic|Drug Toxicity|Drug Side Effect|Drug Mechanism Frede Donskov|Odense University Hospital|Herlev Hospital|Rigshospitalet Denmark|University of Aarhus November 1 2020 --
NCT03735758 Recruiting Drug: pazopanib or guideline conform chemotherapy Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03334409 Recruiting Drug: Ascorbic Acid|Drug: Pazopanib Hydrochloride Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7|Unresectable Renal Cell Carcinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2
NCT03149120 Withdrawn Biological: Nivolumab|Drug: Pazopanib Soft Tissue Sarcomas NYU Langone Health|Bristol-Myers Squibb August 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID